Travere Therapeutics (NASDAQ:TVTX – Get Free Report) announced its earnings results on Monday. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.45), Zacks reports. Travere Therapeutics had a negative net margin of 7.35% and a negative return on equity of 55.15%. The firm had revenue of $224.56 million during the quarter, compared to analyst estimates of $195.29 million. During the same quarter last year, the business earned $0.28 earnings per share. Travere Therapeutics’s revenue was up 36.2% on a year-over-year basis.
Here are the key takeaways from Travere Therapeutics’ conference call:
- Positive Sentiment: FILSPARI U.S. net product sales rose approximately 120% year over year to $200.2 million in Q3, surpassing $200 million for the first time. Management cited strong demand, prescription conversion, and patient persistence across IgA nephropathy and the newly approved FSGS indication.
- Positive Sentiment: FSGS launch momentum was strong, with rapid conversion to paid prescriptions, expanding prescriber adoption, and payer coverage progressing well. Travere said roughly 40% of first-time FSGS prescribers in the quarter were new to FILSPARI, supporting its confidence in achieving or exceeding $3 billion in annual sales by 2033.
- Negative Sentiment: Q3 FILSPARI sales benefited by approximately $8 million from elevated specialty-pharmacy inventory, which is expected to reverse in Q4 as distributors return to normal stock levels. The company also expects higher discounts, with full-year gross-to-net deductions in the mid-20% range.
- Positive Sentiment: The pipeline advanced, with pegtibatinase HARMONY enrollment progressing toward top-line results in the second half of 2027 and civorebrutinib moving toward a U.S. IND submission by year-end. Travere also reported patent progress for FILSPARI that could extend protection in IgA nephropathy and FSGS into 2037.
- Neutral Sentiment: CEO Eric Dube plans to step down in December, with Bradley expected to join as his successor on December 1. Management characterized the transition as occurring from a position of strength, though leadership changes remain an execution consideration for investors.
Travere Therapeutics Price Performance
TVTX traded down $1.13 during trading on Monday, hitting $49.26. The company’s stock had a trading volume of 2,879,492 shares, compared to its average volume of 2,010,109. The company has a current ratio of 4.05, a quick ratio of 3.99 and a debt-to-equity ratio of 24.58. Travere Therapeutics has a twelve month low of $22.59 and a twelve month high of $68.73. The business’s fifty day simple moving average is $59.06 and its 200 day simple moving average is $46.46. The firm has a market capitalization of $4.64 billion, a price-to-earnings ratio of -107.08 and a beta of 1.11.
Analysts Set New Price Targets
Several brokerages have recently commented on TVTX. HC Wainwright reiterated a “buy” rating and set a $67.00 price objective on shares of Travere Therapeutics in a report on Tuesday, September 22nd. Weiss Ratings restated a “sell (e+)” rating on shares of Travere Therapeutics in a research note on Friday, September 18th. TD Cowen upped their target price on Travere Therapeutics from $60.00 to $75.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Canaccord Genuity Group upped their target price on Travere Therapeutics from $62.00 to $70.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Finally, Zacks Research cut Travere Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 20th. Ten equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to MarketBeat, Travere Therapeutics has an average rating of “Moderate Buy” and an average target price of $69.50.
View Our Latest Stock Analysis on TVTX
Insider Buying and Selling at Travere Therapeutics
In related news, CFO Christopher R. Cline sold 50,508 shares of the stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $62.34, for a total value of $3,148,668.72. Following the completion of the transaction, the chief financial officer directly owned 87,508 shares of the company’s stock, valued at approximately $5,455,248.72. This represents a 36.60% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jula Inrig sold 44,674 shares of the firm’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $62.34, for a total value of $2,784,977.16. Following the completion of the transaction, the executive vice president owned 100,491 shares in the company, valued at $6,264,608.94. The trade was a 30.77% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 1,294,029 shares of company stock worth $79,454,261. 4.44% of the stock is currently owned by corporate insiders.
Travere Therapeutics Company Profile
Travere Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases, with an emphasis on serious kidney conditions. The company’s work centers on addressing diseases with limited treatment options and improving outcomes for patients with progressive renal disorders.
Travere’s lead commercial product is FILSPARI (sparsentan), an oral treatment for adults with primary immunoglobulin A nephropathy (IgA nephropathy) who are at risk of disease progression.
Featured Articles
- Five stocks we like better than Travere Therapeutics
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
Receive News & Ratings for Travere Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
